Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 3, 2026, 8:23 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 58 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Intervention: Laser photocoagulation Clear all
Terminated Phase 2 Interventional Results available

A Randomized, Multi-center, Phase II Study of the Safety, Tolerability and Bioactivity of Repeated Intravitreal Injections of iCo-007 as Monotherapy or in Combination With Ranibizumab or Laser Photocoagulation in the Treatment of Diabetic Macular Edema (the iDEAL Study)

NCT01565148
View directory record Official record
Conditions
Diabetic Macular Edema
Interventions
iCo-007 350 mcg, iCo-007 700 mcg, iCo-007 350 mcg and Laser, Ranibizumab and iCo-007 350 mcg
Drug
Lead sponsor
Johns Hopkins University
Other
Eligibility
18 Years and older
Enrollment
185 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2014
U.S. locations
1
States / cities
Omaha, Nebraska
Source: ClinicalTrials.gov public record
Updated Aug 29, 2017 · Synced Sep 3, 2026, 8:23 AM EDT
Completed Phase 1 Interventional

Propranolol for Diabetic Retinopathy

NCT01535495
View directory record Official record
Conditions
Proliferative Diabetic Retinopathy
Interventions
Propranolol
Drug
Lead sponsor
University of Wisconsin, Madison
Other
Eligibility
18 Years and older
Enrollment
9 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2015
U.S. locations
1
States / cities
Madison, Wisconsin
Source: ClinicalTrials.gov public record
Updated Mar 30, 2017 · Synced Sep 3, 2026, 8:23 AM EDT
Completed Phase 3 Interventional Results available

Study to Assess the Efficacy, Safety, and Tolerability of Intravitreal Aflibercept Compared to Laser Photocoagulation in Patients With Retinopathy of Prematurity

NCT04101721
View directory record Official record
Conditions
Retinopathy of Prematurity
Interventions
aflibercept, laser photocoagulation
Drug · Procedure
Lead sponsor
Regeneron Pharmaceuticals
Industry
Eligibility
Not listed
Enrollment
127 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2022
U.S. locations
27
States / cities
Phoenix, Arizona • La Jolla, California • Loma Linda, California + 21 more
Source: ClinicalTrials.gov public record
Updated Jul 19, 2023 · Synced Sep 3, 2026, 8:23 AM EDT
Completed Phase 2 Interventional Results available

A Phase 2 Evaluation of Anti-VEGF Therapy for Diabetic Macular Edema: Bevacizumab (Avastin)

NCT00336323
View directory record Official record
Conditions
Diabetic Retinopathy
Interventions
Laser Photocoagulation, Bevacizumab
Procedure · Drug
Lead sponsor
Jaeb Center for Health Research
Other
Eligibility
18 Years and older
Enrollment
121 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2008
U.S. locations
34
States / cities
Loma Linda, California • Palm Springs, California • Santa Barbara, California + 28 more
Source: ClinicalTrials.gov public record
Updated Aug 25, 2016 · Synced Sep 3, 2026, 8:23 AM EDT
Completed Phase 3 Interventional Results available

Study of Efficacy and Safety of Brolucizumab Versus Panretinal Photocoagulation Laser in Patients With Proliferative Diabetic Retinopathy

NCT04278417
View directory record Official record
Conditions
Proliferative Diabetic Retinopathy
Interventions
Brolucizumab 6 mg, Panretinal photocoagulation laser
Biological · Procedure
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years to 100 Years
Enrollment
689 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2024
U.S. locations
40
States / cities
Tucson, Arizona • Beverly Hills, California • Fullerton, California + 32 more
Source: ClinicalTrials.gov public record
Updated Oct 15, 2025 · Synced Sep 3, 2026, 8:23 AM EDT
Completed Phase 3 Interventional Results available

Intravitreal Triamcinolone Acetonide Versus Laser for Diabetic Macular Edema

NCT00367133
View directory record Official record
Conditions
Diabetic Macular Edema
Interventions
Standard of Care Group, 1mg triamcinolone acetonide, 4mg triamcinolone acetonide
Procedure · Drug
Lead sponsor
Jaeb Center for Health Research
Other
Eligibility
18 Years and older
Enrollment
840 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2008
U.S. locations
84
States / cities
Little Rock, Arkansas • Baldwin Park, California • Beverly Hills, California + 67 more
Source: ClinicalTrials.gov public record
Updated Aug 25, 2016 · Synced Sep 3, 2026, 8:23 AM EDT
Completed Phase 1 Interventional

Laser and Medical Treatment of Diabetic Macular Edema

NCT00027287
View directory record Official record
Conditions
Diabetes Mellitus, Macular Edema
Interventions
Vitamin E
Drug
Lead sponsor
National Eye Institute (NEI)
NIH
Eligibility
Not listed
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2001 – 2002
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Mar 3, 2008 · Synced Sep 3, 2026, 8:23 AM EDT
Completed Not applicable Interventional Results available

Triamcinolone vs. Laser for Diabetic Macular Edema

NCT00229931
View directory record Official record
Conditions
DIABETIC MACULAR EDEMA
Interventions
Triamcinolone acetonide, laser
Drug · Procedure
Lead sponsor
University of Oklahoma
Other
Eligibility
18 Years and older
Enrollment
11 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2013
U.S. locations
1
States / cities
Oklahoma City, Oklahoma
Source: ClinicalTrials.gov public record
Updated Dec 27, 2023 · Synced Sep 3, 2026, 8:23 AM EDT
Not listed Phase 2 Interventional Accepts healthy volunteers

PST/Laser v. Laser Alone for CSME

NCT00229918
View directory record Official record
Conditions
Diabetic Retinopathy
Interventions
triamcinolone acetonide
Drug
Lead sponsor
Edward Hines Jr. VA Hospital
Federal
Eligibility
25 Years to 80 Years · Male only
Enrollment
60 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2005 – 2006
U.S. locations
1
States / cities
Hines, Illinois
Source: ClinicalTrials.gov public record
Updated Sep 29, 2005 · Synced Sep 3, 2026, 8:23 AM EDT
Completed Phase 1Phase 2 Interventional Results available

Efficacy & Safety Trial of Intravitreal Injections Combined With PRP for CSME Secondary to Diabetes Mellitus (DAVE)

NCT01552408
View directory record Official record
Conditions
Diabetic Macular Edema
Interventions
0.3 mg ranibizumab, Targeted Pan Retinal Photocoagulation
Drug · Procedure
Lead sponsor
David M. Brown, M.D.
Other
Eligibility
18 Years and older
Enrollment
29 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2017
U.S. locations
3
States / cities
Houston, Texas • Katy, Texas • The Woodlands, Texas
Source: ClinicalTrials.gov public record
Updated Oct 4, 2018 · Synced Sep 3, 2026, 8:23 AM EDT
Completed Phase 2 Interventional

Triamcinolone Acetonide Injections to Treat Diabetic Macular Edema

NCT00231023
View directory record Official record
Conditions
Diabetic Retinopathy
Interventions
Peribulbar Triamcinolone Acetonide
Drug
Lead sponsor
National Eye Institute (NEI)
NIH
Eligibility
Not listed
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2006
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Mar 3, 2008 · Synced Sep 3, 2026, 8:23 AM EDT
Completed Not applicable Interventional

Laser Photocoagulation in Twin to Twin Transfusion Syndrome

NCT02506049
View directory record Official record
Conditions
Twin to Twin Transfusion Syndrome
Interventions
S-LPC:Selective Laser Photocoagulation
Device
Lead sponsor
University of Tennessee
Other
Eligibility
16 Weeks to 27 Weeks · Female only
Enrollment
1 participant
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2020
U.S. locations
2
States / cities
Memphis, Tennessee
Source: ClinicalTrials.gov public record
Updated Nov 12, 2020 · Synced Sep 3, 2026, 8:23 AM EDT
Completed Phase 1 Interventional

Laser and Antioxidant Treatment of Diabetic Macular Edema

NCT00055042
View directory record Official record
Conditions
Macular Edema, Diabetes Mellitus
Interventions
Vitamin E
Drug
Lead sponsor
National Eye Institute (NEI)
NIH
Eligibility
Not listed
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2004
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Mar 3, 2008 · Synced Sep 3, 2026, 8:23 AM EDT
Completed Phase 3 Interventional Results available

Fluocinolone Acetonide Implant Compared to Sham Injection in Patients With Diabetic Macular Edema

NCT00344968
View directory record Official record
Conditions
Diabetic Macular Edema
Interventions
Fluocinolone Acetonide, Standard of care laser photocoagulation
Drug · Procedure
Lead sponsor
Alimera Sciences
Industry
Eligibility
18 Years and older
Enrollment
956 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2010
U.S. locations
1
States / cities
Atlanta, Georgia
Source: ClinicalTrials.gov public record
Updated May 6, 2014 · Synced Sep 3, 2026, 8:23 AM EDT
Completed No phase listed Observational

The Course of Response to Focal Photocoagulation for DME

NCT00442156
View directory record Official record
Conditions
Diabetic Retinopathy, Diabetic Macular Edema
Interventions
Laser photocoagulation
Procedure
Lead sponsor
Jaeb Center for Health Research
Other
Eligibility
18 Years and older
Enrollment
122 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2008
U.S. locations
32
States / cities
Palm Springs, California • Fort Lauderdale, Florida • Fort Myers, Florida + 26 more
Source: ClinicalTrials.gov public record
Updated Aug 25, 2016 · Synced Sep 3, 2026, 8:23 AM EDT
Completed Phase 2 Interventional Results available

The Ranibizumab for Edema of the mAcula in Diabetes-2 (READ-2) Study

NCT00407381
View directory record Official record
Conditions
Diabetic Macular Edema
Interventions
Ranibizumab, Laser photocoagulation
Drug · Procedure
Lead sponsor
Johns Hopkins University
Other
Eligibility
18 Years and older
Enrollment
126 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2011
U.S. locations
20
States / cities
Phoenix, Arizona • Beverly Hills, California • Los Angeles, California + 16 more
Source: ClinicalTrials.gov public record
Updated Mar 30, 2017 · Synced Sep 3, 2026, 8:23 AM EDT
Completed Phase 1Phase 2 Interventional Results available

HORNBILL: A Study to Test Different Doses of BI 764524 in Patients Who Have Had Laser Treatment for a Type of Diabetic Eye Disease Called Diabetic Retinopathy With Diabetic Macular Ischemia

NCT04424290
View directory record Official record
Conditions
Diabetic Retinopathy
Interventions
BI 764524, Sham control of BI 764524
Drug
Lead sponsor
Boehringer Ingelheim
Industry
Eligibility
18 Years and older
Enrollment
45 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2023
U.S. locations
13
States / cities
Dothan, Alabama • Beverly Hills, California • Palo Alto, California + 10 more
Source: ClinicalTrials.gov public record
Updated May 21, 2024 · Synced Sep 3, 2026, 8:23 AM EDT
Withdrawn Not applicable Interventional

Fetoscopic Laser Photocoagulation in Management of Vasa Previa

NCT06290232
View directory record Official record
Conditions
Vasa Previa, Pregnancy Complications, Maternal; Procedure, In Utero Procedure Affecting Fetus or Newborn
Interventions
Fetoscopic Laser Photocoagulation
Device
Lead sponsor
Boston Children's Hospital
Other
Eligibility
18 Years to 55 Years · Female only
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2028
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jun 1, 2026 · Synced Sep 3, 2026, 8:23 AM EDT
Completed No phase listed Observational

Selective Laser Photocoagulation of Communicating Vessels in Twin-Twin Transfusion Syndrome

NCT01622049
View directory record Official record
Conditions
Twin Twin Transfusion Syndrome
Interventions
Selective Laser Photocoagulation of Communicating Vessels
Device
Lead sponsor
University of South Florida
Other
Eligibility
18 Years to 55 Years · Female only
Enrollment
77 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2009
U.S. locations
1
States / cities
Tampa, Florida
Source: ClinicalTrials.gov public record
Updated Mar 13, 2013 · Synced Sep 3, 2026, 8:23 AM EDT
Completed Phase 3 Interventional Results available

Study of Intravitreal Aflibercept Injection (IAI; EYLEA®; BAY86-5321) in Patients With Diabetic Macular Edema

NCT01363440
View directory record Official record
Conditions
Diabetic Macular Edema
Interventions
Intravitreal Aflibercept Injection (IAI; EYLEA®; BAY86-5321), Macular Laser Photocoagulation
Drug · Procedure
Lead sponsor
Regeneron Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
466 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2014
U.S. locations
51
States / cities
Phoenix, Arizona • Tucson, Arizona • Arcadia, California + 48 more
Source: ClinicalTrials.gov public record
Updated May 29, 2016 · Synced Sep 3, 2026, 8:23 AM EDT
Recruiting No phase listed Observational

Laser Photocoagulation of Communicating Vessels in Twin-to-Twin Transfusion Syndrome

NCT05008744
View directory record Official record
Conditions
Twin to Twin Transfusion as Antepartum Condition, Monochorionic Diamniotic Placenta
Interventions
Fetoscopic laser ablation
Procedure
Lead sponsor
Seattle Children's Hospital
Other
Eligibility
Female only
Enrollment
2,000 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2031
U.S. locations
2
States / cities
Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Apr 18, 2024 · Synced Sep 3, 2026, 8:23 AM EDT
Completed Phase 1Phase 2 Interventional Accepts healthy volunteers Results available

Safety Study of 2.0mg Lucentis to Treat Polypoidal Choroidal Vasculopathy

NCT01469156
View directory record Official record
Conditions
Polypoidal Choroidal Vasculopathy
Interventions
ranibizumab 0.5 or 2.0 mg/0.05 cc
Drug
Lead sponsor
Southeast Retina Center, Georgia
Other
Eligibility
18 Years and older
Enrollment
20 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2011 – 2015
U.S. locations
1
States / cities
Augusta, Georgia
Source: ClinicalTrials.gov public record
Updated Dec 11, 2022 · Synced Sep 3, 2026, 8:23 AM EDT
Not yet recruiting Not applicable Interventional

MoDi Twin Placental Imaging

NCT07667647
View directory record Official record
Conditions
Monochorionic Diamniotic Placenta, Monochorial Monoamniotic Placenta, Monochorionic Twins, Ultrasound Doppler, Ultrasound, Pregnancy, Twin Pregnancy, Monochorionic, Twin Twin Transfusion Syndrome
Interventions
Verasonics Vantage 256 Ultrasound
Device
Lead sponsor
Carilion Clinic
Other
Eligibility
18 Years to 45 Years · Female only
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2029
U.S. locations
1
States / cities
Roanoke, Virginia
Source: ClinicalTrials.gov public record
Updated Jun 24, 2026 · Synced Sep 3, 2026, 8:23 AM EDT
Completed Phase 3 Interventional Results available

Treatment in Preventing Anal Cancer in Patients With HIV and Anal High-Grade Lesions

NCT02135419
View directory record Official record
Conditions
Anal Cancer, High-grade Squamous Intraepithelial Lesion, HIV Infection, Human Papilloma Virus Infection
Interventions
imiquimod, fluorouracil, infrared photocoagulation therapy, thermal ablation therapy, laser therapy, clinical observation, laboratory biomarker analysis
Drug · Device · Other
Lead sponsor
AIDS Malignancy Consortium
Network
Eligibility
35 Years and older
Enrollment
4,446 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2024
U.S. locations
24
States / cities
Los Angeles, California • Palm Springs, California • San Francisco, California + 13 more
Source: ClinicalTrials.gov public record
Updated Jul 25, 2024 · Synced Sep 3, 2026, 8:23 AM EDT